The AR axis remains an important oncogenic driver and therapeutic target for mCRPC.1 Therefore, targeting both oncogenic dependencies may result in improved outcomes in prostate cancer.1,7,8 This QUEST study (ClinicalTrials.gov Identifier: NCT03431350) is a phase II, multicenter, open-label clinical trial designed to evaluate NIRA in combination with other agents in separate cohorts of patients with mCRPC and alterations in genes associated with HRR. Here, AR is linked to prostate carcinoma.